Recent Updates
Recently added Catalysts
MDGL Positive Sentiment Score: 70/100

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

Wednesday, November 6, 2024 1 min read
Key Takeaway: Madrigal Pharmaceuticals, Inc. has announced its participation in three upcoming investor conferences: the UBS Global Healthcare Conference, the Evercore HealthCONx Conference, and the Piper Sandler Healthcare Conference. Presentations at these events will include live webcasts that will be accessible on the company's Investor Relations Events page. This participation underscores Madrigal's efforts to engage with investors while highlighting its focus on treating nonalcoholic steatohepatitis (NASH) using its medication, Rezdiffra.

Conference Participation Details

UBS Global Healthcare Conference
Date: November 11, 2025
Time: 8:45 a.m. ET
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Madrigal Pharmaceuticals will participate in three notable investor conferences which indicates strong investor interest.
  • The company's focus on NASH (nonalcoholic steatohepatitis) highlights its commitment to tackling serious health issues.
  • Webcasts of the presentations provide transparency and accessibility to investors.

Full Press Release Details

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
UBS Global Healthcare Conference 2024
Wednesday, November 13, 2024 at 2:00 P.M. EST
The presentation will be webcast live and may be accessed here.
7th Annual Evercore HealthCONx Conference
Wednesday, December 4, 2024 at 9:35 A.M. EST
Piper Sandler 36th Annual Healthcare Conference
Thursday, December 5, 2024 at 8:30 A.M. EST
The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events page.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Tina Ventura, IR@madrigalpharma.com
Christopher Frates, media@madrigalpharma.com

Tags

Frequently Asked Questions

When is Madrigal's fireside chat at the UBS Healthcare Conference?

Madrigal will participate in the UBS Healthcare Conference on November 13, 2024, at 2:00 P.M. EST.

Where can I watch Madrigal's upcoming investor presentations?

You can access Madrigal's investor presentations live on their Investor Relations Events page.

What is Madrigal Pharmaceuticals focused on?

Madrigal Pharmaceuticals specializes in therapeutics for nonalcoholic steatohepatitis (NASH).

What is Rezdiffra designed to treat?

Rezdiffra (resmetirom) is designed to treat nonalcoholic steatohepatitis (NASH).

When is the Piper Sandler Healthcare Conference?

The Piper Sandler Healthcare Conference is on December 5, 2024, at 8:30 A.M. EST.

Tags: MDGL Viatris Investor Conferences Healthcare Madrigal Pharmaceuticals NASH investor conferences Rezdiffra
Last updated: Nov 6, 2024

Conference Timeline

Nov 11, 2025
UBS Global Healthcare Conference
8:45 AM ET • Fireside Chat
Nov 18, 2025
Jefferies Global Healthcare
11:30 AM GMT • London